Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

HeartMate 3: new challenges in ventricular tachycardia ablation

E. Nof, P. Peichl, P. Stojadinovic, M. Arceluz, P. Maury, M. Katz, UB. Tedrow, RM. Singh, R. Narui, RM. John, WG. Stevenson, R. Beinart, A. Grupper, L. Sternik, J. Lavee, F. Sacher, J. Kautzner, A. Sabbag

. 2022 ; 24 (4) : 598-605. [pub] 20220405

Jazyk angličtina Země Velká Británie

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc22018864

AIM: To describe clinical characteristics, procedural details, specific challenges, and outcomes in patients with HeartMate3TM (HM3), a left ventricular assist device system with a magnetically levitated pump, undergoing ventricular tachycardia ablation (VTA). METHODS AND RESULTS: Data were collected from patients with an HM3 system who underwent VTA in seven tertiary centres. Data included baseline patient characteristics, procedural data, mortality, and arrhythmia-free survival. The study cohort included 19 patients with cardiomyopathy presenting with ventricular tachycardia (VT) (53% with VT storm). Ventricular tachycardias were induced in 89% of patients and a total of 41 VTs were observed. Severe electromagnetic interference was present on the surface electrocardiogram. Hence, VT localization required analysis of intra-cardiac signals or the use of filter in the 40-20 Hz range. The large house pump HM3 design obscured the cannula inflow and therefore multi imaging modalities were necessary to avoid catheter entrapment in the cannula. A total of 32 VTs were mapped and were successfully ablated (31% to the anterior wall, 38% to the septum and only 9% to the inflow cannula region). Non-inducibility of any VT was reached in 11 patients (58%). Over a follow-up of 429 (interquartile range 101-692) days, 5 (26%) patients underwent a redo VT ablation due to recurrent VTA and 2 (11%) patients died. CONCLUSIONS: Ventricular tachycardia ablation in patients with HM3 is feasible and safe when done in the appropriate setup. Long-term arrhythmia-free survival is acceptable but not well predicted by non-inducibility at the end of the procedure.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc22018864
003      
CZ-PrNML
005      
20220804135138.0
007      
ta
008      
220720s2022 xxk f 000 0|eng||
009      
AR
024    7_
$a 10.1093/europace/euab272 $2 doi
035    __
$a (PubMed)34791165
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxk
100    1_
$a Nof, Eyal $u Davidai Arrhythmia Center, Sheba Medical Center, Ramat Gan, Israel $u Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel $1 https://orcid.org/0000000213046070
245    10
$a HeartMate 3: new challenges in ventricular tachycardia ablation / $c E. Nof, P. Peichl, P. Stojadinovic, M. Arceluz, P. Maury, M. Katz, UB. Tedrow, RM. Singh, R. Narui, RM. John, WG. Stevenson, R. Beinart, A. Grupper, L. Sternik, J. Lavee, F. Sacher, J. Kautzner, A. Sabbag
520    9_
$a AIM: To describe clinical characteristics, procedural details, specific challenges, and outcomes in patients with HeartMate3TM (HM3), a left ventricular assist device system with a magnetically levitated pump, undergoing ventricular tachycardia ablation (VTA). METHODS AND RESULTS: Data were collected from patients with an HM3 system who underwent VTA in seven tertiary centres. Data included baseline patient characteristics, procedural data, mortality, and arrhythmia-free survival. The study cohort included 19 patients with cardiomyopathy presenting with ventricular tachycardia (VT) (53% with VT storm). Ventricular tachycardias were induced in 89% of patients and a total of 41 VTs were observed. Severe electromagnetic interference was present on the surface electrocardiogram. Hence, VT localization required analysis of intra-cardiac signals or the use of filter in the 40-20 Hz range. The large house pump HM3 design obscured the cannula inflow and therefore multi imaging modalities were necessary to avoid catheter entrapment in the cannula. A total of 32 VTs were mapped and were successfully ablated (31% to the anterior wall, 38% to the septum and only 9% to the inflow cannula region). Non-inducibility of any VT was reached in 11 patients (58%). Over a follow-up of 429 (interquartile range 101-692) days, 5 (26%) patients underwent a redo VT ablation due to recurrent VTA and 2 (11%) patients died. CONCLUSIONS: Ventricular tachycardia ablation in patients with HM3 is feasible and safe when done in the appropriate setup. Long-term arrhythmia-free survival is acceptable but not well predicted by non-inducibility at the end of the procedure.
650    12
$a kardiomyopatie $x etiologie $7 D009202
650    12
$a katetrizační ablace $x škodlivé účinky $x metody $7 D017115
650    12
$a podpůrné srdeční systémy $7 D006353
650    _2
$a lidé $7 D006801
650    _2
$a recidiva $7 D012008
650    12
$a komorová tachykardie $x diagnóza $x chirurgie $7 D017180
650    _2
$a výsledek terapie $7 D016896
655    _2
$a časopisecké články $7 D016428
700    1_
$a Peichl, Petr $u Department of Cardiology, Institute for Clinical and Experimental Medicine (IKEM), Prague, Czech Republic $1 https://orcid.org/0000000256250071 $7 xx0092197
700    1_
$a Stojadinovic, Predrag $u Department of Cardiology, Institute for Clinical and Experimental Medicine (IKEM), Prague, Czech Republic $1 https://orcid.org/0000000214875823
700    1_
$a Arceluz, Martin $u Section of Cardiac Electrophysiology, Division of Cardiovascular Medicine, Department of Medicine, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, USA
700    1_
$a Maury, Philippe $u Department of Cardiology, University Hospital Rangueil, Toulouse, France
700    1_
$a Katz, Moshe $u Davidai Arrhythmia Center, Sheba Medical Center, Ramat Gan, Israel $u Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel $1 https://orcid.org/0000000203273026
700    1_
$a Tedrow, Usha B $u Cardiovascular Division, Brigham and Women's Hospital, 75 , Boston, MA, USA $1 https://orcid.org/0000000254053744
700    1_
$a Singh, Robin M $u Cardiovascular Division, Brigham and Women's Hospital, 75 , Boston, MA, USA
700    1_
$a Narui, Ryohsuke $u Cardiovascular Division, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA $1 https://orcid.org/0000000211978675
700    1_
$a John, Roy M $u Cardiovascular Division, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA
700    1_
$a Stevenson, William G $u Cardiovascular Division, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA
700    1_
$a Beinart, Roy $u Davidai Arrhythmia Center, Sheba Medical Center, Ramat Gan, Israel $u Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel $1 https://orcid.org/0000000292684766
700    1_
$a Grupper, Avishay $u Davidai Arrhythmia Center, Sheba Medical Center, Ramat Gan, Israel $u Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel $1 https://orcid.org/000000018710650X
700    1_
$a Sternik, Leonid $u Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel $u Department of Cardiac Surgery, Sheba Medical Center, Ramat Gan, Israel $1 https://orcid.org/0000000171809286
700    1_
$a Lavee, Jacob $u Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel $u Department of Cardiac Surgery, Sheba Medical Center, Ramat Gan, Israel $1 https://orcid.org/0000000236411114
700    1_
$a Sacher, Frédéric $u LIRYC Institute, Bordeaux University Hospital, Pessac, France; Department of Cardiac Pacing and Electrophysiology, Bordeaux University Hospital, Pessac, France
700    1_
$a Kautzner, Josef $u Department of Cardiology, Institute for Clinical and Experimental Medicine (IKEM), Prague, Czech Republic $1 https://orcid.org/0000000216326182 $7 xx0037112
700    1_
$a Sabbag, Avi $u Davidai Arrhythmia Center, Sheba Medical Center, Ramat Gan, Israel $u Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel $1 https://orcid.org/0000000342956679
773    0_
$w MED00149837 $t Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology $x 1532-2092 $g Roč. 24, č. 4 (2022), s. 598-605
856    41
$u https://pubmed.ncbi.nlm.nih.gov/34791165 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20220720 $b ABA008
991    __
$a 20220804135132 $b ABA008
999    __
$a ok $b bmc $g 1822450 $s 1170107
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2022 $b 24 $c 4 $d 598-605 $e 20220405 $i 1532-2092 $m Europace $n Europace $x MED00149837
LZP    __
$a Pubmed-20220720

Najít záznam

Citační ukazatele

Možnosti archivace